140 related articles for article (PubMed ID: 15835237)
1. Assessment of corticosteroid-induced alkaline phosphatase as a prognostic indicator in canine lymphoma.
Wiedemann AL; Charney SC; Barger AM; Schaeffer DJ; Kitchell BE
J Small Anim Pract; 2005 Apr; 46(4):185-90. PubMed ID: 15835237
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma.
Keller ET; MacEwen EG; Rosenthal RC; Helfand SC; Fox LE
J Vet Intern Med; 1993; 7(5):289-95. PubMed ID: 8263847
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987-1995).
Valerius KD; Ogilvie GK; Mallinckrodt CH; Getzy DM
J Am Vet Med Assoc; 1997 Feb; 210(4):512-6. PubMed ID: 9040837
[TBL] [Abstract][Full Text] [Related]
4. Analysis of serum corticosteroid-induced alkaline phosphatase isoenzyme in dogs with hepatobiliary diseases.
Kojima K; Ohno K; Kanemoto H; Goto-Koshino Y; Fukushima K; Tsujimoto H
J Small Anim Pract; 2017 May; 58(5):257-262. PubMed ID: 28133732
[TBL] [Abstract][Full Text] [Related]
5. Factors influencing first remission and survival in 145 dogs with lymphoma: a retrospective study.
Baskin CR; Couto CG; Wittum TE
J Am Anim Hosp Assoc; 2000; 36(5):404-9. PubMed ID: 10997515
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy-induced neutropenia is associated with prolonged remission duration and survival time in canine lymphoma.
Wang SL; Lee JJ; Liao AT
Vet J; 2015 Jul; 205(1):69-73. PubMed ID: 26004824
[TBL] [Abstract][Full Text] [Related]
7. Utility of a multiple serum biomarker test to monitor remission status and relapse in dogs with lymphoma undergoing treatment with chemotherapy.
Alexandrakis I; Tuli R; Ractliffe SC; Tappin SW; Foale RD; Roos A; Slater KJ
Vet Comp Oncol; 2017 Mar; 15(1):6-17. PubMed ID: 25319380
[TBL] [Abstract][Full Text] [Related]
8. Treatment of canine non-indolent T cell lymphoma using the VELCAP-TSC protocol: A retrospective evaluation of 70 dogs (2003-2013).
Goodman IH; Moore AS; Frimberger AE
Vet J; 2016 May; 211():39-44. PubMed ID: 27017053
[TBL] [Abstract][Full Text] [Related]
9. Treatment of canine lymphoma with COPLA/LVP.
Boyce KL; Kitchell BE
J Am Anim Hosp Assoc; 2000; 36(5):395-403. PubMed ID: 10997514
[TBL] [Abstract][Full Text] [Related]
10. Assessment of anemia as an independent predictor of response to chemotherapy and survival in dogs with lymphoma: 96 cases (1993-2006).
Abbo AH; Lucroy MD
J Am Vet Med Assoc; 2007 Dec; 231(12):1836-42. PubMed ID: 18081522
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of combination chemotherapy for treatment of gastrointestinal lymphoma in dogs.
Rassnick KM; Moore AS; Collister KE; Northrup NC; Kristal O; Chretin JD; Bailey DB
J Vet Intern Med; 2009; 23(2):317-22. PubMed ID: 19192147
[TBL] [Abstract][Full Text] [Related]
12. High-mobility group B1 proteins in canine lymphoma: prognostic value of initial and sequential serum levels in treatment outcome following combination chemotherapy.
Meyer A; Eberle N; Bullerdiek J; Nolte I; Simon D
Vet Comp Oncol; 2010 Jun; 8(2):127-37. PubMed ID: 20579326
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of a multidrug chemotherapy protocol (ACOPA II) in dogs with lymphoma.
Myers NC; Moore AS; Rand WM; Gliatto J; Cotter SM
J Vet Intern Med; 1997; 11(6):333-9. PubMed ID: 9470157
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of an actinomycin-D-containing combination chemotherapy protocol with extended maintenance therapy for canine lymphoma.
Siedlecki CT; Kass PH; Jakubiak MJ; Dank G; Lyons J; Kent MS
Can Vet J; 2006 Jan; 47(1):52-9. PubMed ID: 16536229
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of a continuous, multiagent chemotherapeutic protocol versus a short-term single-agent protocol in dogs with lymphoma.
Simon D; Moreno SN; Hirschberger J; Moritz A; Kohn B; Neumann S; Jurina K; Scharvogel S; Schwedes C; Reinacher M; Beyerbach M; Nolte I
J Am Vet Med Assoc; 2008 Mar; 232(6):879-85. PubMed ID: 18341445
[TBL] [Abstract][Full Text] [Related]
16. Actinomycin D as rescue therapy in dogs with relapsed or resistant lymphoma: 49 cases (1999--2006).
Bannink EO; Sauerbrey ML; Mullins MN; Hauptman JG; Obradovich JE
J Am Vet Med Assoc; 2008 Aug; 233(3):446-51. PubMed ID: 18673031
[TBL] [Abstract][Full Text] [Related]
17. Outcome and toxicity associated with a dose-intensified, maintenance-free CHOP-based chemotherapy protocol in canine lymphoma: 130 cases.
Sorenmo K; Overley B; Krick E; Ferrara T; LaBlanc A; Shofer F
Vet Comp Oncol; 2010 Sep; 8(3):196-208. PubMed ID: 20691027
[TBL] [Abstract][Full Text] [Related]
18. Retrospective analysis of factors affecting clinical outcome following CHOP-based chemotherapy in dogs with primary nodal diffuse large B-cell lymphoma.
Childress MO; Ramos-Vara JA; Ruple A
Vet Comp Oncol; 2018 Mar; 16(1):E159-E168. PubMed ID: 29152834
[TBL] [Abstract][Full Text] [Related]
19. Combination chemotherapy with continuous L-asparaginase, lomustine, and prednisone for relapsed canine lymphoma.
Saba CF; Hafeman SD; Vail DM; Thamm DH
J Vet Intern Med; 2009; 23(5):1058-63. PubMed ID: 19678892
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of morphological subtypes in canine malignant lymphomas during chemotherapy.
Ponce F; Magnol JP; Ledieu D; Marchal T; Turinelli V; Chalvet-Monfray K; Fournel-Fleury C
Vet J; 2004 Mar; 167(2):158-66. PubMed ID: 14975390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
